MARKET

GNFT

GNFT

Genfit S.A.
NASDAQ
3.780
+0.080
+2.16%
Closed 16:00 12/02 EST
OPEN
3.650
PREV CLOSE
3.700
HIGH
3.793
LOW
3.560
VOLUME
15.60K
TURNOVER
45.97K
52 WEEK HIGH
6.38
52 WEEK LOW
3.010
MARKET CAP
188.30M
P/E (TTM)
4.561
1D
5D
1M
3M
1Y
5Y
Inflation Decline in Germany, Spain Helps Boost European Equities
Inflation Decline in Germany, Spain Helps Boost European Equities
MT Newswires · 5d ago
Genfit reports Q3 results
Seekingalpha · 11/10 22:27
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
NIS2+™ developed and validated as an optimization of NIS4® technology for the detection of patients with at-risk NASHData demonstrate robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-risk NASH, irrespective of p...
GlobeNewswire · 10/25 20:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million.
Benzinga · 10/10 12:10
Genfit GAAP EPS of -€0.21, revenue of €12.19M
Genfit press release (<span class="ticker-hover-wrappe...
Seekingalpha · 09/28 20:52
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
Financial highlights Cash and cash equivalents totaled €209 million as of June 30, 2022Net loss totaled €10 million for the first half 2022 Developments in our programs Patient enrollment for the double-blind part of the Phase 3 study in Primary Biliary Ch...
GlobeNewswire · 09/28 20:10
Earnings Scheduled For September 28, 2022
Companies Reporting Before The Bell • Lilium (NASDAQ:LILM) is expected to report earnings for its second quarter.
Benzinga · 09/28 09:28
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Genfit (NASDAQ:GNFT) shares increased by 27.4% to $5.12 during Thursday&#39;s after-market session. The market value of their outstanding shares is at $255.0 million.
Benzinga · 09/22 21:35
More
About GNFT
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Webull offers kinds of Genfit SA (ADR) stock information, including NASDAQ:GNFT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNFT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNFT stock methods without spending real money on the virtual paper trading platform.